Ertapenem Versus Meropenem/Imipenem for ESBL+ Gram-negative Infections
Launched by MAHIDOL UNIVERSITY · Feb 16, 2011
Trial Information
Current as of May 04, 2025
Unknown status
Keywords
ClinConnect Summary
Ertapenem is active against ESBL-producing Gram negative bacteria. This study is conducted to determine if ertapenem is effective against ESBL-producing Gram negative infections similar to meropenem/imipenem.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Hospitalized patients aged \>18 years with documented ESBL +ve GNB infection
- • Receive meropenem or imipenem/cilastatin as empiric antibiotic therapy
- Exclusion Criteria:
- • Having been treated with meropenem or imipenem/cilastatin for longer than 72 hours
- • Have active P. aeruginosa co-infection
- • Pregnancy or breast feeding
- • Allergy to carbapenems
About Mahidol University
Mahidol University, a premier institution in Thailand, is dedicated to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the university leverages its extensive expertise in medical and health sciences to facilitate rigorous scientific investigations aimed at improving patient care and public health outcomes. With a commitment to ethical practices and collaboration, Mahidol University fosters multidisciplinary approaches, engaging a diverse array of researchers and healthcare professionals to drive meaningful advancements in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bangkok, , Thailand
Patients applied
Trial Officials
Visanu Thamlikitkul, MD
Principal Investigator
Siriraj Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials